title: Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.
authors.affiliation: Research Service, Hines Veterans Affairs Hospital, and the Department of Medicine, Division of Infectious Diseases, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA. stuart.johnson2@va.gov
authors.forename: Stuart
authors.initials: S
authors.lastname: Johnson
authors.forename: Dale N
authors.initials: DN
authors.lastname: Gerding
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Louie
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Ruiz
authors.forename: Sherwood L
authors.initials: SL
authors.lastname: Gorbach
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D016360:Clostridioides difficile / Q000187:drug effects*; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology; D023381:Endpoint Determination; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000382:microbiology; D000077732:Fidaxomicin; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D011108:Polymers / Q000627:therapeutic use; D013451:Sulfonic Acids; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D011108:Polymers; D013451:Sulfonic Acids; D008795:Metronidazole; D014640:Vancomycin; D000077732:Fidaxomicin; C077114:styrenesulfonic acid polymer